Immunocytochemical localization of BCL‐2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy

International Journal of Cancer

Volumn 59, Issue 5, 1994, Pages 619-628

  Gee, Julia M W ^a   Robertson, John F R ^b   Ellis, Ian O ^b   Willsher, Peter ^b   McClelland, Richard A ^a   Hoyle, Helen B ^a   Kyme, Susan R ^a   Finlay, Pauline ^a   Blamey, Roger W ^b   Nicholson, Robert I ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GOSERELIN; ONCOPROTEIN; TAMOXIFEN; TAMOXIFEN CITRATE;

ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS;

APOPTOSIS; BREAST NEOPLASMS; CELL NUCLEUS; CYTOPLASM; EPITHELIUM; FEMALE; GOSERELIN; HUMAN; IMMUNOENZYME TECHNIQUES; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SUPPORT, NON-U.S. GOV'T; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR MARKERS, BIOLOGICAL;

EID: 0027970798     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.2910590508     Document Type: Article

References (28)

1. Apoptotic cell death induced by c‐myc is inhibited by bcl‐2
2. Assessment of response to treatment in advanced breast cancer
3. bcl‐2 expression in invasive mammary carcinoma: correlation with apoptosis, hormone receptors and p53 expression
4. Wild‐type p53 mediates apoptosis by EIA, which is inhibited by EIB
5. bcl‐2 protoonco‐gene expression in normal and neoplastic human myeloid cells
6. The prevalence of bcl‐2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status
7. Role of bcl‐2 in growth factor triggered signal transduction
8. Assessment of response to therapy in advanced breast cancer
9. bcl‐2 is an inner mitochondrial membrane protein that blocks programmed cell death
10. Expression of bcl‐2 in small cell lung carcinoma cells
11. Short term tamoxifen induces the cytoplasmic expression of c‐erbB‐2 and bcl‐2 in ER‐positive human primary breast cancer
12. bcl‐2 in normal human breast and carcinoma, association with oestrogen receptor‐positive, epidermal growth factor receptor‐negative tumours and in situ cancer
13. bcl‐2 expression in adult and embryonic non‐haematopoietic tissues
14. Oestrogen receptor analysis: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies
15. Expression of the protooncogene bcl‐2 in the prostate and its association with emergence of androgen‐independent prostate cancer
16. Relationships of S‐phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival
17. bcl‐2 oncoprotein blocks chemotherapy‐induced apoptosis in a human leukemia cell line
18. Expression in non‐Hodgkin's lymphoma of the bcl‐2 protein associated with the t(14;18) chromosomal translocation
19. Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation
20. Relationship between EGFR, c‐erbB‐2 protein expression and Ki‐67 immunostaining in breast cancer and hormone sensitivity
21. Transforming growth factor‐alpha and endocrine sensitivity in breast cancer
22. Deregulated bcl‐2 gene expression selectively prolongs survival of growth factor‐deprived hemopoietic cell lines
23. Immunocytochemical localisation of estrogen and progesterone receptors
24. Molecular mechanism of stomach carcinogenesis
25. Structure‐function analysis of the bcl‐2 oncoprotein. Addition of a heterologous transmembranedo‐main to portions of the bcl‐2 beta protein restores function as a regulator of cell survival
26. Effect of bcl‐2 protooncogene expression on cellular sensitivity to tumour necrosis factor‐mediated cytotoxicity
27. Toward an understanding of the molecular mechanisms of physiological cell death
28. myc‐mediated apoptosis is blocked by ectopic expression of bcl‐2